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Abstract Highly polymorphic major histocompatibility complex (MHC) molecules are at the heart
of adaptive immune responses, playing crucial roles in many kinds of disease and in vaccination. We
report that breadth of peptide presentation and level of cell surface expression of class I molecules
are inversely correlated in both chickens and humans. This relationship correlates with protective
responses against infectious pathogens including Marek’s disease virus leading to lethal tumours in
chickens and human immunodeficiency virus infection progressing to AIDS in humans. We propose
that differences in peptide binding repertoire define two groups of MHC class I molecules
strategically evolved as generalists and specialists for different modes of pathogen resistance. We
suggest that differences in cell surface expression level ensure the development of optimal
peripheral T cell responses. The inverse relationship of peptide repertoire and expression is evidently
a fundamental property of MHC molecules, with ramifications extending beyond immunology and
medicine to evolutionary biology and conservation.
DOI: 10.7554/eLife.05345.001
Introduction
Highly polymorphic class I molecules encoded by the major histocompatibility complex (MHC) are
crucial in the adaptive immune response to viruses and some intracellular bacteria, binding peptides
inside the cell and presenting them on the cell surface to CD8 T lymphocytes (Blum et al., 2013;
International HIV Controllers Study et al., 2013; Trowsdale and Knight, 2013). The impact of the
MHC in response to human immunodeficiency virus (HIV) is well recognized, with class I alleles like
HLA-B*35:01 leading to rapid onset of AIDS while HLA-B*57:01 and HLA-B*27:05 confer long-term
non-progression (Carrington et al., 1999; Goulder and Walker, 2012; International HIV Controllers
Study et al., 2013). Various explanations for these associations have been suggested, including
antigen presentation of a particularly effective peptide or of a number of peptides to cytotoxic CD8
T cells or recognition (primarily) independent of peptide by natural killer (NK) cells (Carrington et al.,
1999; Martin et al., 2002; Kosmrlj et al., 2010; International HIV Controllers Study et al., 2013).
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Recently, the level of cell surface expression of HLA-C alleles correlated with CD8 T cell cytotoxicity
has been proposed as one important basis for control (Thomas et al., 2009; Apps et al., 2013).
Understanding how cell expression level might impact on disease resistance is complicated in humans
due to the presence of three class I loci, so we began by studying a simpler animal system before
examining human class I alleles.
Long ago, we reported that the relative expression level of MHC class I molecules on the surface of
chicken red blood cells as assessed by flow cytometry varies significantly, with cells of the MHC
haplotype B21 approximately ten-fold lower than B4, B12, B15, and B19 (Kaufman et al., 1995). This
finding was of interest because the level of cell surface expression is inversely correlated with the
reported levels of MHC-determined resistance to Marek’s disease, an economically important disease
caused by the oncogenic herpesvirus, Marek’s disease virus (MDV). Decades of investigation
identified B21 (and other haplotypes like B2, B6, and B14) as generally conferring resistance and B19
(and other haplotypes such as B4, B12, and B15) as generally conferring susceptibility (reviewed in
Plachy et al., 1992). On this basis, we proposed that MHC-determined resistance to Marek’s disease
could be due to the cell surface expression polymorphism of class I molecules (Kaufman et al., 1995;
Kaufman and Salomonsen, 1997).
Compared to humans, the chicken MHC is relatively simple (Kaufman et al., 1999), with two
classical class I genes BF1 and BF2 that flank the genes for the transporter associated with antigen
presentation (TAP). The TAP transporter pumps peptides from the cytoplasm to the lumen of the
endoplasmic reticulum for loading nascent class I molecules, and in typical mammals is functionally
monomorphic, pumping a wide variety of peptides for all members of the polymorphic class I
multigene family. In contrast, chicken TAP genes are highly polymorphic, with each haplotype
encoding a TAP molecule with a peptide-translocation specificity matching the peptide-binding
specificity of the dominantly expressed class I molecule encoded by the BF2 gene, with the BF1 gene
expressed poorly or not at all (Wallny et al., 2006; Shaw et al., 2007; Walker et al., 2011).
In chickens, the peptide-binding specificity of the dominantly expressed class I molecule can
determine resistance to infectious pathogens as well as responses to vaccines. The peptide motifs
eLife digest Our immune system has the remarkable ability to recognize and destroy damaged
cells or invading microbes while leaving the healthy cells in the body alone. Groups of proteins called
‘MHC class I molecules’ play important roles in defence against invading microbes. If a cell becomes
infected with a virus or a bacterium, these molecules can recognize and bind to fragments of foreign
or unusual proteins inside the cell, and display them on the surface of the cell. This allows immune
cells to identify and kill the infected cells.
Cells produce many different MHC class I molecules that are able to bind to different protein
fragments. Some MHC molecules can bind to a wider variety of protein fragments than others, and
the number of these molecules present on the cell surface can also vary between individuals.
Researchers have noticed that individuals with particular MHC molecules tend to be more or less
resistant to particular diseases. For instance, individuals with certain MHC molecules tend to take
longer to develop AIDS if they become infected with HIV. However, it is not clear how either the
variety of protein fragments bound or the numbers of MHC class I molecules on the surface of cells
could alter the immune response.
Here, Chappell, Meziane et al. studied MHC class I molecules in chickens and humans. The
experiments reveal that the MHC class I molecules that can bind to a larger variety of protein
fragments (so-called ‘generalists’) are present in lower numbers on the surface of cells than
molecules that can bind to a smaller variety of fragments (so-called ‘specialists’).
Furthermore, generalist MHC molecules were found to provide resistance to Marek’s disease in
chickens—which causes paralysis—but some specialists slowed the progression of HIV infections into
AIDS in humans. Chappell, Meziane et al. propose that these two types of MHC class I molecules
evolved to perform different roles in immune responses. This is a new way of looking at the role of
MHC molecules in fighting disease, and the next challenge is to explore the implications for medicine
and evolutionary biology.
DOI: 10.7554/eLife.05345.002
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from B4, B12, B15, and B19 class I molecules are if anything more fastidious than human and mouse
motifs, with only one or two amino acids found at the positions of anchor residues, with the motifs
explaining the immune response to infection and vaccination (Kaufman et al., 1995). The fastidious
binding of these molecules could be easily understood from wire models of the binding site, in which
charged and hydrophobic residues were found in appropriate places to interact in a simple manner
with the anchor residues of the bound peptides (Wallny et al., 2006). This view was confirmed from
the crystal structure of the dominantly expressed class I molecule BF2*0401 from the B4 haplotype,
with positive-charged residues in a narrow groove allowing only certain anchor residues from the
peptide to be accommodated (Zhang et al., 2012). In contrast, much less peptide material was
isolated from B21 cells, with many amino acids found in every peptide position. Crystal structures
demonstrated that the dominantly expressed class I molecule BF2*2101 remodels the binding site to
accommodate two peptides with completely different sequences, including the anchor residues (Koch
et al., 2007). Thus, the lack of a clear peptide motif could be explained as promiscuous peptide
binding due to the remodelling of the peptide-binding site.
In this paper, we find that two other haplotypes known to confer resistance to Marek’s disease also
have low cell surface expression and promiscuous peptide motifs, and examine the structural basis for
promiscuous binding in three low expressing molecules. We show that the same relationship between
cell surface expression and peptide-binding repertoire is found for four human class I molecules,
associated with progression to AIDS. Finally, we propose how promiscuous peptide binding might
confer resistance to some pathogens, what the basis for the cell surface expression polymorphism
might be, and how these properties may relate to different strategies for resistance to pathogens.
Results
Chicken class I molecules show an inverse correlation between cell
surface expression and peptide-binding repertoire
We reported that the relative level of class I molecules on the surface of erythrocytes is ten-fold lower
for adult chickens of the B21 MHC haplotype compared to the B4, B12, B15, and B19 haplotypes, as
assessed by flow cytometry with two different monoclonal antibodies (mAb) (Kaufman et al., 1995).
Extending this work, we examined another cell type, spleen lymphocytes, with a quantitative flow
cytometric assay using a mAb to chicken heavy chain. We found a similar rank order for these and
other haplotypes (Figure 1), with the difference
between the highest and lowest ranging up to
fourfold over many experiments. The B2, B14,
and B21 haplotypes can be considered as ‘low-
expressing haplotypes’, while B4, B12, B15, and
B19 haplotypes are ‘high-expressing haplotypes’,
with low-expression correlating historically with
resistance to Marek’s disease.
For the high-expressing haplotypes B4, B12,
B15, and B19, the dominantly expressed class I
molecules all have definite peptide motifs, with
two or three peptide positions each bearing one
or two chemically similar residues (Kaufman
et al., 1995; Wallny et al., 2006). In contrast,
much less peptide material was isolated from low
expressing B21 cells, with pool sequences show-
ing many amino acids in every peptide position
(Koch et al., 2007). Extending this work, we
sequenced pools of peptides from erythrocytes
and leukocytes of chickens with B2 and B14
haplotypes and found that they also showed
many amino acids in each position, mostly with
very different chemical characteristics
(Figure 2A). Sequencing of single peptides from
B2, B14, and B21 haplotypes confirmed this
Figure 1. Cell surface expression levels of class I
molecules vary markedly between chicken haplotypes,
as determined by a quantitative flow cytometric assay.
Spleen cells from various inbred experimental chicken
lines (with MHC haplotypes indicated) were stained with
the monoclonal antibody F21-2 against chicken major
histocompatibility complex (MHC) class I heavy chain
and the specific antigen binding capacity (SABC, which
reflects number of epitopes per cell calculated in
reference to specific antibody-binding calibration
beads). Results are means of triplicate stains, with error
bars indicating standard deviation.
DOI: 10.7554/eLife.05345.003
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sequence diversity, with no obvious anchor positions bearing one or two residues with similar
chemical characteristics (Figure 2B).
Thus, the chicken class I molecules from high-expressing haplotypes have clear peptide motifs, at
least as fastidious as such motifs described in humans and mice. In contrast, the class I molecules from
Figure 2. Peptides isolated from class I molecules of B2, B14, and B21 chickens show promiscuity of peptide
binding. For all panels, amino acids are in single letter code, with basic residues shown in blue, acidic in red, polar in
green, hydrophobic in black. (A) Sequences of peptides bound to class I molecules isolated from three chicken
strains determined from peptide pools showing apparent anchor, strong and weak signals. (B) Sequences of
individual peptides, with confirmed anchor residues in bold. (C) Peptide anchor residues in large letters (or question
marks for unknown) superimposed on a model of class I α1 and α2 domains with those residues of the major (above)
and minor (below) class I sequences that are both polymorphic and potentially peptide contacts indicated as smaller
letters; numbering based on human class I (HLA-A2) sequence.
DOI: 10.7554/eLife.05345.004
Chappell et al. eLife 2015;4:e05345. DOI: 10.7554/eLife.05345 4 of 22
Research article Immunology
low-expressing haplotypes have no obvious peptide motifs, with promiscuous binding unlike what has
been described in mammals. To confirm that these properties result in different numbers of distinct
peptides on the cell surface, we isolated class I molecules from equal numbers of cells from the B19
cell line 265L and the B21 cell line AVOL-1, and analysed the bound peptides by mass spectrometry.
Despite the B19 line having twice as many class I molecules on the cell surface as the B21 line as
assessed by quantitative flow cytometry, there were only one third as many distinct peptides
identified by mass spectrometry (Figure 3). Thus, a promiscuous class I molecule can and does bind
a greater variety of peptides that appear on the surface of the cells, in comparison to a fastidious
molecule.
The low-expressing BF2*2101 molecule remodels the binding site to
accommodate a variety of peptides with very different anchor
residues
Unlike high-expressing haplotypes (Wallny et al., 2006), the wire models of the dominantly expressed
class I of the B21 haplotype, BF2*2101, gave no clue as to which peptides might bind (Figure 2C).
Crystal structures, based on heavy chain and β2-microglobulin (β2m) expressed in bacteria and
refolded with synthetic peptides, showed that BF2*2101 remodels the binding site to accommodate
two peptides with completely different sequen-
ces, including the anchor residues (Koch et al.,
2007). Small residues bordering the groove lead
to a large cavity in the middle of the groove,
within which Asp24 and Arg9 can move, creating
different configurations, as illustrated for the
11mer peptide GHAEEYGAETL and the 10mer
peptide REVDEQLLSV (Figure 4A,B). The pep-
tide position P2 His of the 11mer interacts with
the Asp24, while the Pc-2 Glu interacts with the
Arg9 (and Pc Leu fits in a hydrophobic pocket at
the end of the groove). The 10mer remodels the
binding site, so that the P2 Glu interacts with
Asp24 that also interacts with Arg9 in a so-called
charge transfer mechanism, creating a hydropho-
bic pocket that accommodates Pc-2 Leu (and Pc
Val fits in the hydrophobic pocket).
Additional peptides eluted from MHC mole-
cules of B21 cells (Figure 2B) show that other
amino acids at P2 and Pc-2 can be accommodated
by the critical Asp24 and Arg9 within the large
central cavity in the binding site. In fact, the
10mer TNPESKVFYL binds BF2*2101 in similar
way to the 10mer REVDEQLLSV (Table 1,
Figure 4C), with P2 Asn binding the Asp24 aided
by charge transfer with Arg9, and with the
rearrangement of Arg9 permitting the accom-
modation of Pc-2 Phe, just as for Pc-2 Leu in the
previous structure.
However, the two structures with the 10mers
TAGQEDYDRL and TAGQSNYDRL display a com-
pletely different mode of binding (Table 1,
Figure 4D,E), for which the P2 Ala does not
interact with the MHC molecule at all (and
therefore is not an anchor residue), with Arg9
interacting as a bridge between Asp24 and Pc-2
Asp. A further mode of binding is shown by the
10mer YELDEKFDRL (Table 1, Figure 4F), for
which both anchor residues at positions P2 and
Figure 3. There is an inverse correlation between the
cell surface expression levels of class I molecules and
the variety of peptides isolated from class I molecules.
(A) The B19 cell line 265L and the B21 cell line AVOL-1
were analysed by flow cytometry by staining with the
mAb F21-2 to chicken class I molecules. AVOL-1 had
slightly more autofluorescence, so the settings on the
FACScan were adjusted so that the mean fluorescence
intensity of the isotype control sample was the same as
for 265L. The histogram shows the fluorescence intensity
in the FL1 channel on the x-axis and the number of
events on the y-axis. (B) In the same flow cytometry
experiment, the calibration beads from the QIFIKIT were
stained separately with the secondary antibody for
calibration curves to calculate the SABC, which reflects
the absolute numbers of epitopes on the cell surface.
As a separate experiment, the class I molecules were
isolated from each cell line by affinity chromatography
with F21-2 and analysed by LC-MS/MS. Table shows the
SABC and the number of different peptides found for
each cell line.
DOI: 10.7554/eLife.05345.005
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Pc-2 are acidic. In this structure, the P2 Glu
interacts with both Asp24 and Arg9, and Pc-2
Asp interacts with Arg9. These various modes of
binding are presumably just a few out of many
and illustrate the promiscuous binding of
BF2*2101, unlike anything seen for mammalian
class I molecules.
The low expressing BF2*0201 and
BF2*1401 molecules bind a variety
of peptides through broad
hydrophobic pockets
Similar to B21, the peptides isolated from cells of
the low expressing haplotypes B2 and B14 have
no obvious motifs. Pool sequences show no
position at which only one or two chemically
similar amino acids are present as anchor
residues (Figure 2A). Individual peptides have
no classic pattern of anchor residues, but some
features are discernable (Figure 2B).
The B2 peptides fall into two groups. One
small group of peptides has P2 Arg and mostly P1
Arg and Pc Tyr (Figure 2B), much like the
dominantly expressed class I molecule of the
high-expressing B15 haplotype, BF2*1501
(Wallny et al., 2006). These three peptides are
likely to have been isolated from the poorly
expressed molecule encoded by the minor gene
of the B2 haplotype, BF1*0201, the wire model of
which (Figure 2C) looks very similar to BF2*1501.
Size exclusion chromatography (SEC) of heavy
chain and β2m expressed in bacteria and refolded
with peptide showed that BF1*0201 but not
BF2*0201 binds these peptides (Figure 5).
All of the other B2 peptides have generally
smaller hydrophobic amino acids at P2 and
somewhat larger hydrophobic amino acids at Pc
(Figure 2B). Crystal structures with two of these
peptides (Table 1, Figure 6A,B), YPYLGPNTL
and VIFPAKSL, show that Pro and Ile at peptide
position P2 and Leu at Pc bind shallow hydro-
phobic pockets (Figure 6A,B), similar to the way
in which anchor residues bind pockets B and F in
many mammalian class I molecules. This mode of
binding is completely different from BF2*2101
that remodels the binding site, despite the fact
that BF2*0201 shares Asp24 and Arg9 with
BF2*2101. In these BF2*0201 structures, Arg9
interacts mostly with peptide main chain atoms
and Asp24 interacts with Tyr43 (residue 45 being
the equivalent position in human class I molecules), a residue that differs between BF2*0201 and
BF2*2101, ultimately leading to a more hydrophobic pocket B to accommodate P2 residues
(Figure 6A,B).
The B14 peptides all share two features, generally a medium to large hydrophobic amino acid at P2
and one or more basic amino acids at the end of the peptide (Figure 2B). A wire model of BF2*1401
shows small hydrophobic and polar residues in and around the beginning of the groove and reveals
Figure 4. Structures of BF2*2101 with different peptides
show several modes of promiscuous binding through
remodelling of the binding site. Left panels, top down
view with peptide as sticks (N-terminus to the left;
carbon atoms, yellow; nitrogen atoms, blue; oxygen
atoms, red) and class I molecule as solid surface (grey
except for positions of Asp24 side chain oxygen atoms
in pink and Arg9 side chain nitrogen atoms as cyan).
Right panels, side view from α2 domain side with
peptide, Asp24 and Arg9 as sticks (hydrogen bonds,
dotted lines; carbon atoms of Asp24 and Arg9, white; all
else as in left panels). (A) GHAEEYGAETL (peptide P316;
PDB 3BEV); (B) REVDEQLLSV (P330; 3BEW); (C)
TNPESKVFYL (P458; 2YEZ); (D) TAGQEDYDRL (P394;
4D0B); (E) TAGQSNYDRL (P399; 4D0C); (F) YELDEKFDRL
(P400; 4CVZ).
DOI: 10.7554/eLife.05345.006
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many acidic residues at the end of the groove, well placed to interact with the basic residues at the
peptide C-terminus (Figure 2C). The crystal structure of peptide SWFRKPMTR bound to BF2*1401
shows that Trp at position P2 interacts with hydrophobic surfaces in pocket B, while Arg at Pc interacts
with Asp73(human position 74), Asp76(77) and Asp113(116) in pocket F (Table 1, Figure 6C). Both
these pockets are much deeper in BF2*1401 compared to BF2*0201, which explains the larger anchor
residues found in the B14 peptides compared to most B2 peptides. The differences in pocket sizes are
primarily due to difference in size between Val43(45) and Tyr43(45) for pocket B and between Asp113
(116) and Met113(116) for pocket F, which are supported by a network of hydrogen bonds from Thr24
and Gln9 in BF2*1401 and from Asp24 and Arg9 in BF2*0201 (Figure 6).
These data show that the three class I molecules with lower expression on the cell surface all bind
a wide range of peptides with no obvious peptide motif, although the mechanism by which the
promiscuous binding is achieved is different for each molecule. One feature that may be important is
the width of the peptide-binding groove (Figure 7), which is the narrowest in the high expressing
BF2*0401 molecule (Zhang et al., 2012) and the widest in the low expressing BF2*2101.
Table 1. Data collection and refinement statistics
PDBID 4d0b 4d0c 4cvz 2yez 4cvx 4d0d 4cw1
Data collection
Space group P212121 P212121 P212121 P212121 P65 P212121 P212121
Cell dimensions
a, b, c (A˚) 60.9 60.5 60.5 60.6 173.9 88.1 62.2
69.2 68.9 69.0 69.0 173.9 92.5 90.58
95.4 94.8 93.7 94.8 87.5 223.6 144.8
α, β, γ (˚) 90 90 90 90 90 90 90
90 90 90 90 90 90 90
90 90 90 90 120 90 90
Resolution (A˚) 56.03–2.80
(2.95–2.80)
51.00–2.82
(2.89–2.82)
50.84–2.39
(2.56–2.39)
41.03–2.45
(2.58–2.45)
75.66–3.30
(3.56–3.30)
88.08–3.13
(3.21–3.13)
72.38–2.58
(2.65–2.58)
Rsym or Rmerge 0.118 (0.30) 0.12 (0.30) 0.15 (0.91) 0.07 (0.22) 0.17 (0.56) 0.18 (0.69) 0.14 (0.59)
I/σI 8.1 (2.8) 8.2 (1.9) 11.9 (2.1) 9.5 (1.5) 11.1 (3.8) 8.8 (2.1) 8.8 (2.3)
Completeness (%) 91.2 (89.8) 90.8 (76.0) 99.9 (100) 85.9 (53.0) 100 (99.9) 99.6 (98.8) 99.3 (98.4)
Redundancy 4.0 (3.6) 3.8 (1.9) 6.4 (6.5) 2.8 (1.6) 7.3 (7.5) 4.6 (4.4) 5.5 (4.2)
Refinement
Resolution (A˚) 56.03–2.80 50.92–2.81 50.84–2.39 41.03–2.45 75.66–3.30 88.08–3.13 72.38–2.58
No. reflections 9361 8967 16,086 8913 21,707 32,916 26,228
Rwork/Rfree 27.5/29.6% 27.5/28.2% 25.9/26.9% 25.2/27.3% 23.8/26.2% 29.2/29.9% 28.6/29.1%
Number of atoms
Protein 3061 3057 3079 3091 6052 12,102 6044
Ligand/ion 0 4 24 0 0 0 0
Water 5 31 42 30 8 9 77
B-factors
Protein 30.30 34.24 30.23 32.22 77.86 47.02 40.02
Ligand/ion – 26.32 46.25 – – – –
Water 14.33 12.88 24.38 8.61 34.87 34.31 29.50
Root mean square (r.m.s.) deviations
Bond lengths (A˚) 0.008 0.007 0.007 0.007 0.004 0.007 0.007
Bond angles (˚) 0.89 0.86 0.85 0.83 0.759 0.82 0.84
Highest resolution shell is shown in parenthesis.
DOI: 10.7554/eLife.05345.007
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Human class I molecules also show an inverse correlation between cell
surface expression and peptide-binding repertoire
The structural analysis of BF2*2101 showed that this low expressing class I molecule achieves
promiscuous binding by remodelling the peptide binding site in a way never described for
a mammalian class I molecule. However, analysis of BF2*0201 and BF2*1401 shows promiscuous
binding by chicken molecules using anchor positions into pockets B and F, much like many mammalian
classical class I molecules. In order to determine whether the inverse correlation between cell surface
Figure 5. The dominantly expressed class I molecule BF2*0201 binds VIFPAKSL but not RRALREGY, while the
minor class I molecule BF1*0201 binds RRALREGY but not VIFPAKSL. (A and B) Size exclusion chromatography
(SEC) traces for BF2*0201 or BF1*0201 heavy chains expressed in bacteria refolded with or without β2-
microglobulin (β2m) and peptide. The heavy chain BF2*0201 refolded with β2m and the appropriate
peptide migrates as a native monomer, whereas refolded with the inappropriate or no peptide migrates in the
same position as heavy chain alone. In contrast, all these conditions for the heavy chain BF1*0201 result in
molecules that migrate roughly the same mobility. (C through F) Mass spectrometry (MALDI-TOF) analysis of
the monomer peaks of heavy chain refolded with β2m and peptide shows that VIFPAKSL but not RRALREGY can
be recovered from BF2*0201, while RRALREGY but not VIFPAKSL can be recovered from BF1*0201. Note the
many peaks for BF1*0201 with VIFPAKSL and for BF2*0201 with RRALREGY, representing background
contaminants detected as sensitivity was increased in the search for the synthetic peptide. Comparable results
were obtained with YPYLGPNTL, RRALREGY, RRGGVKRI, and the B15 (BF2*1501) peptide KRLIGKRY.
DOI: 10.7554/eLife.05345.008
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expression level and peptide binding promiscuity is a feature just of chickens or is indicative of a more
fundamental property, we examined some human class I alleles.
Only a few studies have explored the extent of the peptide-binding repertoire of different human
class I molecules. One of these studies reported the predicted peptide-binding repertoires for four
human class I alleles, finding a rank hierarchy from the extremely fastidious HLA-B*57:01 to HLA-B*27:
05 to HLA-B*07:02 to the highly promiscuous HLA-B*35:01, that correlated directly with progression
from HIV infection to AIDS (Kosmrlj et al., 2010). The rank hierarchy of these alleles is the same as
that determined by binding of peptide libraries (Paul et al., 2013).
We identified two mAbs reported (Apps et al., 2009) to react with all four HLA-B alleles (along
with HLA-C alleles, which are poorly expressed on blood cells), but not with certain HLA-A alleles.
Volunteers with the proper combinations of homozygous HLA-A and HLA-B alleles were recruited
from a large group of bone marrow donors (Table 2), and the cell surface expression levels on their
blood lymphocytes and monocytes were examined by quantitative flow cytometry. The two mAb
(Tu149 and B1.23.2) reacted with all four HLA-B alleles and gave similar (but not identical) results for
both lymphocytes and monocytes, with a rank hierarchy in cell surface expression ranging from HLA-
B*57:01 as the highest to HLA-B*27:05 to HLA-B*07:02 to HLA-B*35:01 as the lowest (Figure 8A–D).
One potential concern with these data was that the difference in expression level of the HLA-B
alleles might actually be due to differences in HLA-C levels, which are known to vary between alleles
(Thomas et al., 2009; Apps et al., 2013). However, inspection shows that there is no correlation of
expression levels reported for the HLA-C alleles found for the individual donors and the expression
level of the mAb binding (Table 2), if anything the reverse with the low expressing HLA-B*35:01
donors all having HLA-C alleles reported to have high expression.
Figure 6. Structures of BF2*0201 and BF2*1401 show promiscuous binding via hydrophobic binding pockets for the
anchor residues at peptide position P2 and Pc, with the class I residues at positions 24 and 9 playing supporting
roles, and with residues lining the pockets explaining the relative size of anchor residues. Upper panels, side view
from α2 domain side with peptide as sticks (N-terminus of peptide to the left; carbon atoms of peptide, yellow;
carbon atoms of class I molecule, white; nitrogen atoms, blue; oxygen atoms, red; hydrogen bonds, dotted lines;
carbon atoms of Asp24 and Arg9, white). Middle (pocket B) and bottom (pocket F) panels, side view cut-away from
α2 domain side with peptide and selected class I residues as sticks (numbering based on chicken class I sequence)
and with rest of MHC molecule as solid surface. (A) YPYLGPNTL bound to BF2*0201 (peptide P377; PDB 4CVX);
(B) VIFPAKSL bound to BF2*0201 (P473; 4D0D); (C) SWFRKPMTR bound to BF2*1401 (P479; 4CW1).
DOI: 10.7554/eLife.05345.009
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Another concern was that the difference in
expression level of the HLA-B alleles actually
reflects differences in affinity of binding by the
two mAb. The fact that both antibodies gave
similar but non-identical results suggests that
they do not recognize exactly the same epitopes
and therefore are unlikely by chance to vary
similarly in affinity. We tested whether the two
antibodies bound independently and found that
B1.23.2 inhibited both itself and Tu149 very well,
while Tu149 inhibited both itself and B1.23.2
much less well (Figure 9). These results suggest
that B1.23.2 has a much higher affinity than
Tu149 and that their epitopes overlap. We also
utilized a third antibody (22E-1) that reacts with
the HLA-B*57:01 and HLA-B*27:05 but not HLA-
B*07:02 and HLA-B*35:01 (nor with any HLA-C
allele), and therefore must recognize a different
epitope. We found the same relationship of
expression level for HLA-B*57:01 and HLA-
B*27:05 as with the other two antibodies
(Figure 8E,F).
Thus, in humans the high expressing class I
molecules have fastidious peptide binding, and
the low expressing molecules have promiscuous
binding. We conclude that the correlation be-
tween peptide-binding repertoire and expression
level is the same in chickens and humans and is
indicative of a fundamental property of class I
molecules.
Discussion
In this article, we make three major points.
First, we extend previous work showing that the
chicken BF2*2101 achieves promiscuity by
remodelling the peptide binding site in a way
unknown for mammals, but we find that two
other low expressing chicken class I molecules
achieve promiscuity with the same pockets
typically used in mammals. By extension, these
latter results provide a potential molecular
explanation for recent reports that human class
I molecules vary in peptide repertoire and other
reports that they vary in cell surface expression
level. Second, we show that peptide-binding
repertoire and level of cell surface expression
are inversely correlated in both chickens and
humans, indicating that this relationship is
a fundamental property of class I molecules.
Finally, we find that there is a clear association
with resistance to infectious diseases, with the
low expressing promiscuous class I molecules
associated with resistance to Marek’s disease in chickens but associated with faster progression to
AIDS in humans. We discuss each of these points in turn.
The first point is the structural and mechanistic basis for differences in peptide repertoire of
chicken class I molecules. In this article, we confirm and extend the finding (Koch et al., 2007) that
Figure 7. Structures of chicken class I molecules show
differences in the width of the peptide-binding groove,
with the fastidious BF2*0401 having the narrowest
groove and the promiscuous BF2*2101 being the widest
in the centre of the groove. Top down view with peptide
as sticks (N-terminus to the left; carbon atoms, yellow;
nitrogen atoms, blue; oxygen atoms, red) and class I
molecule as grey solid surface. (A) VIFPAKSL
bound to BF2*0201 (P473; 4D0D); (B) IDWFEGKE
bound to BF2*0401 (IE8; 4G43); (C) SWFRKPMTR bound
to BF2*1401 (P479; 4CW1); (D) YELDEKFDRL bound to
BF2*2101 (P400; 4CVZ).
DOI: 10.7554/eLife.05345.010
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BF2*2101 binds 10mer and 11mer peptides with three anchor positions, with many different amino
acids with different chemical characteristics, mostly charged and polar at positions P2 and Pc-2
(and hydrophobic at Pc), which is unlike any mammalian molecule described thus far. In contrast, we
find that BF2*0201 and BF2*1401 bind 8mer and
9mer peptides with two anchor residues (much
like typical mammalian class I molecules), each
with a variety of amino acids at P2 and Pc.
One question is why BF2*2101 and BF2*0201
bind in such different ways, given that both have
Asp24 and Arg9 in their binding sites. In part, this
may be due to the difference in residues lining
the peptide-binding groove. In BF2*2101, small
residues like Gly68(human position 69), Ser69
(70), Ser97(99), and Gly152(155) create a big
cavity in the centre of the binding groove,
allowing Asp24 and Arg9 to move. In BF2*0201
and BF2*1401, the two Ser residues are replaced
by the large residues Asn69(70) and Tyr97(99),
creating a constricted groove much more like
narrow grooves found in high expressing fastid-
ious molecules such as BF2*0401. It is also
possible that the length of peptides is deter-
mined at least in part by TAP specificity.
Together, the narrower groove and the shorter
peptides ensure that Asp24 and Arg9 in
BF2*0201 (as well as Thr24 and Gln9 in
BF2*1401) cannot reach the P2 and Pc-2 positions,
and thus they interact (if at all) with the main
chain atoms of the peptide.
Another question is how chicken class I
molecules BF2*0201 and BF2*1401 compare to
human molecules like HLA-A2, all of which bind
Table 2. Anonymized donors with class I alleles and inferred HLA-C expression
Donor HLA-A alleles HLA-B alleles HLA-C alleles HLA-C expression
5701/02 02:01, 02:01 57:01, 57:01 06:02, 15:02 high, unknown
5701/03 01:01, 01:01 57:01, 57:01 06:02, 06:02 high, high
5701/04 01:01, 03:01 57:01, 57:01 06:02, 07:01 high, low
2705/1 03:01, 68:01 27:05, 27:05 01:02, 02:02 high, high
2705/2 02:06, 11:01 27:05, 27:05 01:02, 03:03 high, low
2705/3 02:01, 02:01 27:05, 27:05 01:02, 12:03 high, high
2705/4 02:01, 02:12 27:05, 27:05 unknown
0702/1 02:01, 03:01 07:02, 07:02 07:02, 07:02 low, low
0702/2 03:01, 03:01 07:02, 07:02 07:02, 07:02 low, low
0702/3 02:01, 03:01 07:02, 07:02 07:02, 07:02 low, low
0702/4 03:01, 11:01 07:02, 07:02 07:02, 07:02 low, low
3501/1 11:01, 11:01 35:01, 35:01 04:01, 04:01 high, high
3501/2 11:01, 11:01 35:01, 35:01 04:01, 04:01 high, high
3501/3 03:01, 03:01 35:01, 35:01 04:01, 04:01 high, high
3501/4 11:01, 11:01 35:01, 35:01 04:01, 04:01 high, high
DOI: 10.7554/eLife.05345.011
Figure 8. Human class I molecules show an inverse
correlation between cell surface expression level and
peptide binding promiscuity. Levels of specific antibody
binding capacity (SABC) for different mAb: (A and B)
Tu149, (C and D) B1.2.23, (E and F) 22E-1 for (A, C and E)
ex vivo lymphoctyes and (B, D and F) ex vivo monocytes.
Each point represents the sample from a particular
donor (identified with anonymous labels that correlate
with haplotypes in Table 2; donor B57:01/01 failed to
donate); bars indicate the mean for each HLA-B allele.
DOI: 10.7554/eLife.05345.012
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peptides with hydrophobic anchor residues.
HLA-A2 has one of the widest peptide reper-
toires among human class I molecules, as
assessed by peptide-binding studies (Paul
et al., 2013). The anchor residues for HLA-A2
fit into narrow and specific-binding pockets,
which allow almost only P2 Met and Leu for
pocket B and Pc Val and Leu for pocket F
(Guo et al., 1993). Although Leu and Val in
particular are relatively common in proteins (so
that the number of peptides bearing these amino
acids should be relatively high), there is a much
larger number of hydrophobic amino acids that
are accommodated by the shallower pockets in
both BF2*0201 and BF2*1401. Hence, it seems
likely that the peptide repertoire of the most
promiscuous chicken class I molecules will be
greater than the most promiscuous human class I
molecules.
Finally, are there obvious mechanisms by
which differences in peptide repertoire arise? In
chickens, the peptides presented depend on the
peptide-binding specificities of the class I molecule, but also on the peptide-translocation specificities
of the TAPs and perhaps also on peptide-editing by tapasin. The genes for chicken TAP and tapasin
have at least as many alleles as class I genes (Walker et al., 2005, 2011; van Hateren et al., 2013).
On this basis, we propose that the difference in peptide repertoire (and in cell surface expression
level) between chicken class I alleles is determined at the level of peptide loading and editing, likely to
take place mostly in the peptide-loading complex. It might not be immediately apparent whether such
an explanation could account for the differences in peptide repertoire and cell surface expression of
human class I molecules, since human TAPs and tapasin are functionally monomorphic. However,
a recent paper suggests that the assembly and cell surface expression of different HLA-B alleles is
determined by interaction with the near invariant tapasin molecule, based on variation in the certain
HLA-B residues (Rizvi et al., 2014). Indeed, it is striking that the rank order of expression level that we
find for the four HLA-B alleles tested is exactly the same as the rank order of tapasin dependence
found in this recent paper.
The second important point for discussion is why the cell surface expression would be inversely
correlated with peptide-binding repertoire. A proximal explanation might be that the biochemical
mechanism of peptide loading, as mentioned in the paragraph above, leads to this relationship.
Another explanation, similar to the suggestion that multiple MHC molecules lead to a greater chance
of autoimmunity (Kaufman et al., 1995), is that promiscuous class I molecules confer more resistance
to pathogens but also lead to greater autoimmunity compared to fastidious class I molecules.
We favour a third possibility, prompted by the experimental and supporting theoretical evidence
for the notion that a greater number of MHC loci would lead to greater level of negative selection in
the thymus (Vidovic´ and Matzinger, 1988; Nowak et al., 1992). In a similar way, one might expect
that class I molecules presenting a lesser variety of peptides would negatively select fewer T cell
clones, but class I molecules presenting a greater variety of peptides would negatively select many
more T cells and create a pauperized T cell repertoire. Therefore, we propose that the peptide-
binding repertoire and the cell surface expression levels are inversely correlated precisely to allow
similar numbers of T cell clones to survive negative selection and be available in the periphery. In this
view, low expressing and promiscuous class I molecules might present many more peptides but each
individual peptide would be present on the surface at a much lower level, so that T cells would escape
the negative selection that might have occurred at a higher concentration of a particular MHC-
peptide complex. In essence, we propose that peptide-binding repertoires and cell surface
expression levels have evolved to optimize peripheral T cell responses. Many papers have examined
naı¨ve CD8 T cell repertoire in humans and mice (for example, Alanio et al., 2010; Jenkins and Moon,
2012; Lo et al., 2014); such analyses with high and low expressing haplotypes would be informative.
Figure 9. The epitopes on HLA-B57:01 for mAb B1.23.2
and Tu149 are overlapping, with B1.23.2 having
a much higher affinity. Win cells were treated with
saturating amounts of unlabelled Tu149 (blue), saturat-
ing amounts of unlabelled B1.23.2 (green) or PBS (red),
and then stained with either A Tu149 conjugated to APC
or B B1.23.2 conjugated to Alexa Fluor 647. Results were
compared to staining with only isotype control (grey).
DOI: 10.7554/eLife.05345.013
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The third important point for discussion is the fact that the inverse correlation between peptide
binding repertoire and cell surface expression level also correlates with resistance and susceptibility to
certain infectious pathogens. One important question is how it might work.
In chickens, these phenomena are correlated with MHC-determined resistance to historic Marek’s
disease. Many genetic loci contribute to resistance to Marek’s disease, but historically the B locus
(containing the MHC) was by far the most important, and under strong selection by MDV (Plachy et al.,
1992; Vallejo et al., 1998). Here, we show that the low expressing promiscuous class I molecules are
associated with resistance to Marek’s disease, while the high expressing fastidious class I molecules are
associated with susceptibility. A consequence of promiscuous binding is that these low expressing class
I molecules present a larger repertoire of peptides which should activate a wider range of T cell clones,
which may be beneficial in the immune response to certain pathogens. We propose that this breadth of
antigen presentation leads to a breadth of T cell response that is the basis of MHC-determined
resistance to Marek’s disease. Conversely, a narrow T cell response to Marek’s disease would be the
basis for MHC-determined susceptibility, and there is already evidence for a limited repertoire of CD8
T cell clones infiltrating tumours in susceptible B19 chickens (Mwangi et al., 2011). Parenthetically, if
true this model suggests that the narrowing of CD8 T cell clonality characteristic of responses in
humans and mice (Yewdell and Bennink, 1999; Yewdell and Del Val, 2004; Akram and Inman, 2012)
may not be a feature of responses involving promiscuous class I molecules in chickens.
For our example in humans, however, we find the opposite disease association. We find that the
low expressing promiscuous HLA-B alleles are associated with rapid progression from HIV infection to
AIDS, while the high expressing fastidious HLA-B alleles are found in non-progressors (Carrington
et al., 1999; Goulder and Walker, 2012; International HIV Controllers Study et al., 2013). The
correlation with peptide binding repertoire (as assessed by prediction) of HLA-B alleles had already
been noted (Kosmrlj et al., 2010), but the relationship with cell surface expression level has not. The
controller alleles HLA-B*57:01 and HLA-B*27:05 are known to bind and present particular viral
peptides that are both protective and difficult for the virus to change without a loss in fitness
(Gillespie et al., 2006; Schneidewind et al., 2007). Thus, particular class I molecules may be selected
because their fastidious motif presents a particularly protective peptide.
Is there an obvious evolutionary basis for differences in peptide-binding repertoire? The fact that
the fastidious HLA-B*57:01 confers resistance to AIDS while the promiscuous BF2*2101 confers
resistance to Marek’s disease may be no paradox, in that breadth of peptide presentation may be an
appropriate response to some pathogens, while presentation of a particular peptide may be more
suitable for other pathogens. Viewed from this perspective, the work presented in this paper has
begun to define two groups (or a range between two extremes) of class I molecules that are
strategically evolved for different modes of resistance.
One possible strategy is that fastidious class I molecules with pauci-clonal T cell responses might be
better suited for rapidly evolving viruses with a limited scope for immune evasion, for which
a particular peptide might be the most efficient way to achieve resistance. In contrast, promiscuous
class I molecules might be better suited for pathogens with coding potential for many immune evasion
genes and more stability over evolutionary time, such as large DNA viruses, bacteria, and even
parasites. There are few reports about pathogen peptides that are presented in chickens, but the
large literature on the MHC restriction of viruses, bacteria, and parasites in humans and mice (for
example, Fitzmaurice et al., 2015; Goulder and Walker, 2012; Macnamara et al., 2010; Moss and
Khan, 2004; Steven et al., 1997; Yim and Selvaraj, 2010) may be reinterpreted, as the peptide
repertoire and cell surface expression levels of the class I molecules become known.
Another potentially fruitful way of considering the strategies of class I molecules (not necessarily
exclusive of the first view) might be as generalists and specialists. There is a large literature in biology
that examines the generalist/specialist paradigm at the species level, typically testing the model that
‘the jack of all trades is the master of none’ (McArthur, 1972; Futuyma and Moreno, 1988). Recent
examples, among many others, include breadth of diet by insect herbivore species (Ali and Agrawal,
2012), niche breadth by bird species (Julliard et al., 2006), competition on shared hosts by aphid
parasitoids (Straub et al., 2011), and weasel predation of voles (Sundell and Ylo¨nen, 2008), as well as
mathematical models to disentangle the contributions by various factors (Remold, 2012; Bu¨chi and
Vuilleumier, 2014). Indeed, the terms generalist and specialist MHC alleles have already been used
for describing correlations of class II alleles of the striped mouse in Africa with number of nematode
species carried (Froeschke and Sommer, 2012).
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In this view, the promiscuous class I molecules would be generalists, which one might expect to
suffice for protection against a wide variety of the most common pathogens. However, such
generalists might not suffice for protection from a new and/or an especially virulent pathogen that
suddenly appears, at which point there would be a strong selection for a specialist class I molecule
that was particularly suited to deal with the new threat. The properties of fastidious class I molecules
are consistent with selection as specialists for particular pathogens, perhaps including those no longer
a danger in the current population.
The importance of these concepts for immunology and medicine may be clear from the discussion
above, but there are also ramifications for evolutionary biology, ecology, and conservation. As one
example, the number of MHC alleles is considered a key measure for population diversity in
estimating the risk of extinction, both as a measure of overall genome diversity and in terms of fitness,
including resilience to infection (Sommer, 2005). However, a population with a few generalist MHC
alleles might remain healthy compared to a population with many inappropriate specialist MHC
alleles.
Materials and methods
Cells
Ex vivo chicken cells were from inbred chicken lines with known MHC haplotypes (Shaw et al., 2007),
kept at the University of Cambridge. All procedures were performed under appropriate Home Office
Licenses and after review by the Ethics Committee at the University of Cambridge. Spleens were
mashed through 100-μm nylon cell strainers (Falcon) in RPMI-1640 medium, supernatants taken after
5 min settling, and spleen cells recovered after centrifugation at 400×g for 5 min. All procedures were
carried out under Home Office licenses and with ethical approval.
Chicken cell lines were from the Pirbright Institute. AVOL-1 was derived from in vitro
transformation of spleen cells from a line 0 (B21) chicken by the reticuloendotheliosis virus REV-T
(Smith, 2004; Yao et al., 2008; W Mwangi and V Nair, unpublished data). The MDCC-265L cell line
was established from a liver lymphoma of a line P2a (B19) chicken infected with the RB-1B virus
derived from a BAC clone (as in Yao et al., 2009; W Mwangi and V Nair, unpublished data). Both lines
were maintained in RPMI 1640 medium containing 10% foetal bovine serum, 10% tryptose phosphate
broth and 1% sodium pyruvate, and at 38.5˚C in 5% CO2.
Ex vivo human cells were from Anthony Nolan registrants typed as homozygous for particular
HLA-A and HLA-B locus alleles, who signed written consent forms, and with all procedures carried
out under Human Tissue Act licenses and with ethical approval. Blood samples were collected by
general practice or Walk-in Clinic phlebotomists and were couriered to the Anthony Nolan
Research Institute within 24 hr. Whole blood was diluted 1:1 upon arrival with transport media
(RPMI 1640 [Lonza, Belgium] supplemented with 0.6% tri-sodium citrate and 50 nM 2-
mercaptoethanol), and most samples were rocked at room temperature overnight. In a similar
manner as originally described for cord blood (Figueroa-Tentori et al., 2008), peripheral blood
mononuclear cells were isolated (all steps at 20˚C) using a density gradient centrifugation
(Ficoll–Paque Plus 1077, GE Healthcare) at 840×g for 30 min with no brake, with the buffy coat
washed twice with two volumes RPMI-1640 media, spun once at 680×g for 10 min and once at
540×g for 10 min. All samples were stained, fixed, and anonymized before transfer to Cambridge
for analysis by flow cytometry.
The human homozygous HLA-B*57 typing cell line WIN (alias IHW9095 from 10th International
Workshop, gift of W Bultitude and S Marsh, Anthony Nolan Research Institute) was maintained in
RPMI1640 with 10% foetal bovine serum and 1 mM glutamine in 5% CO2 at 37˚C.
Flow cytometry
As described by instructions for quantitative flow cytometry from manufacturer (QIFIKIT, Dako) and
following previous work (Smith and Ellis, 1999), 5 × 105 cells were incubated on ice in 96-well
(U-bottom for chicken, V-bottom for human) microtiter plates (Nunc) with saturating primary antibody
followed by washing and then by incubation with goat anti-mouse secondary antibody conjugated to
fluorescein followed by washing, and data acquired using a FACscan (Becton-Dickenson). Set-up
beads and calibration beads were stained separately with the secondary antibody for calibration
curves to calculate the specific antigen binding capacity, which reflects the absolute numbers of
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epitopes on the cell surface. Primary mAb include 200 μl tissue culture supernatant of mouse mAb
F21-2 for chicken class I molecules (Crone et al., 1985) and three that react with certain HLA-B
antigens but not certain HLA-A alleles (Apps et al., 2009): 200 μl tissue culture supernatant of Tu149
(Uchan´ska-Ziegler et al., 1993; gift of J Trowsdale, University of Cambridge), 20 μl 1 mg/ml B1.2.23
(Rebaı¨ and Malissen, 1983; bought from eBioscience) diluted in PBS and 20 μl 1 mg/ml 22E1 (Tahara
et al., 1990; bought from Caltag Medsystems) diluted in PBS. Saturation was confirmed by staining
with dilutions of antibodies on each set of cells, except for human ex vivo cells, for which saturation
was confirmed by staining WIN cells.
For the inhibition assay, Tu149 conjugated to APC (Invitrogen; kind gift of S Ashraf and J
Trowsdale, University of Cambridge) and purified B1.23.2 conjugated to Alexa Fluor 647 (purified
mAb from eBioscience conjugated using the Antibody Labeling kit, Molecular Probes/Life
Technologies, according to manufacturer’s instructions) were used. As above, 5 × 105 WIN cells
were incubated with saturating amounts of unlabelled B1.23.2 or Tu149 (or with PBS) for 1 hr, washed
and then incubated with a directly labelled antibody for 1 hr, before washing the cells again. Data
were acquired using the red laser on a Cytek FACSanalyser (Becton Dickinson).
Peptides from ex vivo chicken cells
Inbred chicken lines, with known MHC haplotypes (Shaw et al., 2007), were kept at the Institute for
Animal Health at Compton. All procedures were performed under appropriate Home Office
Licenses and after review by the Ethics Committee at the Institute for Animal Health. As previously
described (Wallny et al., 2006; Koch et al., 2007), erythrocytes (or whole mashed up spleens) were
solubilized in detergent, and class I molecules were isolated by affinity chromatography using mAb
F21-2 against chicken class I molecules or F21-21 against chicken β2m. Peptides were eluted using
trifluoroacetic acid and separated by reverse phase high-pressure liquid chromatography with
single peaks of abundant peptides as well as pools of non-abundant peptides sequenced by Edman
degradation.
Peptides from chicken cell lines
Immunoaffinity beads were produced, with all steps at room temperature. Protein G-Sepharose
beads (Expedeon) were washed with 50 mM borate, 50 mM KCl, pH 8.0, the equivalent of 1-ml
packed beads was incubated with 3 mg F21-2 (produced by the Microbiological Media Services of
the Pirbright Institute) for 1 hr, treated with 40 mM dimethyl pimelimidate dihydrochloride
(Sigma) in 0.1 M triethanolamine, pH 8.3 for 1 hr to cross-link the antibody to the protein G,
washed with 100 mM citric acid pH 3.0, and equilibrated in 50 mM Tris, pH 8.0. The two cell lines
AVOL1 and 265L were washed with PBS. Pellets of 109 cells were incubated with 10 ml 1% Igepal
630, 300 mM NaCl, 100 mM Tris pH 8.0 for 30 min at 4˚C, subcellular debris was pelleted by
centrifugation at 300×g for 10 min and 15,000×g for 30 min at 4˚C, and the cleared lysates were
incubated with 1 ml immunoaffinity beads for 1 hr at 4˚C. The beads were washed with 50 mM
TrisCl, pH 8.0 buffer, first with 150 mM NaCl, then with 400 mM NaCl and finally with no salt.
Bound material was eluted with 10% acetic acid. The eluted material was dried, resuspended in
3% acetonitrile, 0.1% formic acid in water, loaded directly onto on a 4.6 × 50 mm ProSwiftTM
RP-1S column (ThermoFisher) and eluted at 500 μl/min flow rate for 10 min with a linear gradient
from 2 to 35% buffer B (0.1% formic acid in acetonitrile) in buffer A (0.1% formic acid in water)
using an Ultimate 3000 HPLC system (ThermoFisher), with fractions collected from 2 to 15 min.
Protein detection was performed at 280 nm absorbance, with fractions eluting before β2m pooled
and dried.
For liquid chromatography tandem mass spectrometry (LC-MS/MS), peptides were analysed
using either a Q-Exactive (Thermo Scientific) or a TripleTOF 5600 (AB Sciex) system. For the Q-
Exactive system, peptides were separated on a Ultimate 3000 RSLCnano System utilizing
a PepMap C18 column, 2 μm particle size, 75 μm × 50 cm (Thermo Scientific) with a linear
gradient from 3% to 35% buffer B in buffer A (as above) at a flow rate of 250 nl/min (∼65 MPa) for
60 min, and the 15 most intense precursors per full MS scan were selected for MS/MS analysis
using HCD fragmentation. For the TripleTOF system, peptides were separated with a 15 cm × 75
μm ChromXP C18-CL (3 μm particle size) using an ekspert nanoLC 400 cHiPLC system (Eksigent)
with a linear gradient from 8% to 35% buffer B in buffer A (as above) at a flow rate of 300 nl/min
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(∼1600 psi) for 60 min, and CID fragmentation was induced on the 30 most abundant ions per full
MS scan. All fragmented precursor ions were actively excluded from repeated selection for 15 s.
Data were analysed using Peaks 7 (Bioinformatics Solutions) using a database containing all
24,092 Uniprot entries for the organism Gallus gallus combined with protein translations (>8
amino acids) of either all six reading frames of gallid herpesvirus 2 (NCBI entry NC_002229.3;
10,026 entries) or reticuloendotheliosis virus (NC_006934.1; 412 entries). Results were filtered
using a false discovery rate of 1% that was determined by parallel searching of a randomized
decoy database.
Expression and assembly of class I molecules
As previously described (Koch et al., 2007), the extracellular sequence of mature BF2*2101 heavy
chain and chicken β2m cloned in pET22b(+) were expressed separately as inclusion bodies in BL21
(λDE3) pLysS Rosetta bacterial cells, solubilized in urea and assembled together with synthetic
peptide (synthesized commercially by fluorenyl-methoxy-carbonyl [fMOC] chemistry) by dilution in
a renaturation buffer. Assembled class I molecules were isolated after SEC using a HiLoad 26/60
Superdex 200 column (GE Healthcare, UK). Similar procedures were used for BF1*0201, BF2*0201
and BF2*1401, except that a codon-optimized gene was synthesized (GenScript) for BF2*0201, which
was then cloned into a pET28a(+) vector followed by a factor X site for cleavage, a BirA site for
biotinylation and a His tag for purification (Leisner et al., 2008).
Assembly assays
As previously described (Koch et al., 2007),
heavy chains and β2m were expressed in bacteria
as inclusion bodies and denatured in urea; β2m
was refolded and purified by SEC. For each
renaturation sample, solutions containing 30 μg
heavy chain plus or minus 42 μg β2m and/or 10
μg synthetic peptide were added to refold buffer
and incubated at 4˚C with stirring for roughly 40
hr. After centrifugation and passage through
a 0.45-μm sterile filter, each sample was loaded
on a Superdex 200 10/300 GL SEC column (GE
Healthcare, UK) as part of an AKTA 920 with 100
mM NaCl, 25 mM TrisCl, pH 8.0 running at 1 ml/
min at room temperature. Peak fractions were
Table 3. Crystallization conditions, data collection, and refinement information
Structure
(PDB ID) Crystallization conditions Cryo-protectant Beamline Data processing
Refinement
program
4 d0b 0.1M MMT buffer, pH 5.0,
25% PEG 1500
15% ethylene glycol I02 (Diamond Light Source) AUTOPROC SUITE with
XDS & SCALA
AUTOBUSTER
4d0c 0.05M KH2PO4,
20% PEG 8000
20% ethylene glycol I02 (Diamond Light Source) XIA2 with XDS & AIMLESS AUTOBUSTER
2yez 0.1M MMT buffer,
pH 4.0, 25% PEG 1500
15% ethylene glycol I03 (Diamond Light Source) AUTOPROC SUITE with
XDS & SCALA
AUTOBUSTER
4cvz 0.1M sodium acetate,
pH 5.0, 1.5 M ammonium
sulphate
8M sodium formate I04-1 (Diamond Light Source) XIA2 with XDS & AIMLESS AUTOBUSTER
4cvx 0.1M MMT buffer,
pH 7.0, 25% PEG 1500
15% ethylene glycol I04 (Diamond Light Source) XIA2 with XDS & AIMLESS REFMAC
4 d0d 0.1M MMT buffer,
pH 7.0, 25% PEG 1500
15% ethylene glycol I04 (Diamond Light Source) XIA2 with XDS & AIMLESS AUTOBUSTER
4cw1 0.1M MIB buffer,
pH 5.0, 25% PEG 1500
15% ethylene glycol ID29 (ESRF) XIA2 with XDS & AIMLESS AUTOBUSTER
DOI: 10.7554/eLife.05345.014
Table 4. Ramachandran statistics
Structure
(PDB ID)
Ramachandran
outliers
number (%)
Ramachandran
favoured
number (%)
4cvz 0 (0%) 371 (98.15%)
4 d0b 0 (0%) 356 (94.43%)
4d0c 0 (0%) 361 (95.76%)
2yez 1 (0.26%) 364 (96.04%)
4cvx 0 (0%) 710 (95.69%)
4 d0d 0 (0%) 1430 (96.30%)
4cw1 0 (0%) 730 (98.25%)
DOI: 10.7554/eLife.05345.015
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collected and concentrated first using a pre-rinsed Amicon Ultra-4 10 kDa column and then
a Vivaspin 500 10 kDa column to roughly 100 μl, buffer-exchanged into 50 mM NaCl, 10 mM Tris, pH
8.0, concentrated to roughly 20 μl, and then transferred into a polypropylene microfuge tube.
Acetic acid was added to 5% and the sample was concentrated to 2–4 μl using a SpeedVac at 40˚C
before analysis by MALDI-TOF (Protein and Nucleic Acid Chemistry services, Department of
Biochemistry, University of Cambridge).
Crystallography
Recombinant MHC class I complexes were crystallized using the sitting-drop method (see Table 3 for
conditions). Crystals were flash frozen in liquid nitrogen and native data sets for each crystal were
collected at 100K [Diamond Light Source, Harwell (beamlines I02, I03, I04 or I04-1), or the ESRF,
Grenoble (beamline ID29)]. Data were processed using either AUTOPROC (Vonrhein et al., 2011) or
XIA2 (Winter, 2010) with XDS (Kabsch, 2010) for integration and AIMLESS (Evans, 2006) or SCALA
(Evans and McCoy, 2008) for scaling. All structures were solved by molecular replacement, as
implemented in Phaser (McCoy et al., 2007), part of the CCP4 software package (Winn et al., 2011).
Starting molecular replacement models were generated using CHAINSAW (Stein, 2008) and the
atomic co-ordinates of the chicken B21 MHC class I molecule (PDBID: 3BEV) with the peptide
removed. Model building and refinement were carried out using COOT (Emsley et al., 2010) and
AUTOBUSTER (Bricogne et al., 2011) or REFMAC (Murshudov et al., 1997), with the heavy and light
chains of the MHC molecule rebuilt first before the peptide was modelled into residual electron
density (see Table 1 for refinement statistics, Table 3 for data collection and refinement information,
Table 4 for Ramachandran statistics).
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